DE69228474D1 - STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER - Google Patents

STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER

Info

Publication number
DE69228474D1
DE69228474D1 DE69228474T DE69228474T DE69228474D1 DE 69228474 D1 DE69228474 D1 DE 69228474D1 DE 69228474 T DE69228474 T DE 69228474T DE 69228474 T DE69228474 T DE 69228474T DE 69228474 D1 DE69228474 D1 DE 69228474D1
Authority
DE
Germany
Prior art keywords
igg antibodies
monoclonal human
stabilized treatment
state
monoclonal antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69228474T
Other languages
English (en)
Other versions
DE69228474T2 (de
Inventor
Hideaki Hagiwara
Hideo Yuasa
Yasunori Yamamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
HAGIWARA YOSHIHIDE TAKARAZUKA HYOGO JP
Original Assignee
HAGIWARA YOSHIHIDE TAKARAZUKA HYOGO JP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16495593&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69228474(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by HAGIWARA YOSHIHIDE TAKARAZUKA HYOGO JP filed Critical HAGIWARA YOSHIHIDE TAKARAZUKA HYOGO JP
Application granted granted Critical
Publication of DE69228474D1 publication Critical patent/DE69228474D1/de
Publication of DE69228474T2 publication Critical patent/DE69228474T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
DE69228474T 1991-07-20 1992-07-17 STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER Expired - Fee Related DE69228474T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP3204743A JP2966592B2 (ja) 1991-07-20 1991-07-20 安定化されたヒトモノクローナル抗体製剤
PCT/JP1992/000914 WO1993001835A1 (en) 1991-07-20 1992-07-17 Stabilized human monoclonal antibody preparation

Publications (2)

Publication Number Publication Date
DE69228474D1 true DE69228474D1 (de) 1999-04-01
DE69228474T2 DE69228474T2 (de) 1999-06-24

Family

ID=16495593

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69228474T Expired - Fee Related DE69228474T2 (de) 1991-07-20 1992-07-17 STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER

Country Status (6)

Country Link
EP (1) EP0597101B1 (de)
JP (1) JP2966592B2 (de)
AT (1) ATE176868T1 (de)
AU (1) AU662010B2 (de)
DE (1) DE69228474T2 (de)
WO (1) WO1993001835A1 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1082368C (zh) * 1995-03-21 2002-04-10 应用研究系统Ars股份公司 人绒毛膜促性腺激素液体制剂
EP0814841B1 (de) 1995-03-21 2001-12-05 Applied Research Systems ARS Holding N.V. Flüssige hcg-formulierungen
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
PL189381B1 (pl) * 1997-01-30 2005-07-29 Bioph Biotech Entw Pharm Gmbh Rekonstytuowany MP52 oraz sposób wytwarzania rekonstytuowanego MP52
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
ES2644275T3 (es) 2000-08-11 2017-11-28 Chugai Seiyaku Kabushiki Kaisha Preparaciones estabilizadas que contienen anticuerpos
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
AU2003211991B2 (en) 2002-02-14 2008-08-21 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution formulations
PL1610820T5 (pl) 2003-04-04 2014-01-31 Genentech Inc Preparaty zawierające wysokoskoncentrowane przeciwciała i białka
FR2853551B1 (fr) * 2003-04-09 2006-08-04 Lab Francais Du Fractionnement Formulation stabilisante pour compositions d'immunoglobulines g sous forme liquide et sous forme lyophilisee
SI1698640T2 (sl) * 2003-10-01 2019-08-30 Kyowa Hakko Kirin Co., Ltd. Postopek za stabiliziranje protitelesa in stabiliziran pripravek protitelesa tipa raztopina
CA2590337C (en) 2004-12-15 2017-07-11 Neuralab Limited Humanized amyloid beta antibodies for use in improving cognition
GT200600031A (es) * 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
RU2011140498A (ru) 2009-03-06 2013-04-20 Дженентек, Инк. Препарат антител
BR122019026701B1 (pt) * 2012-03-26 2023-01-24 Sanofi Formulações de agentes de ligação à base de igg4 estáveis, kit, e dispositivo ou recipiente pré-cheios
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5347515A (en) * 1976-10-13 1978-04-28 Green Cross Corp:The Gamma-globulin pharmaceutical preparation for intravenous injection
JPS56127320A (en) * 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Gamma-globulin pharmaceutical
US4808621A (en) * 1986-07-07 1989-02-28 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted)pyrazol-4-yl)-ethyl]- or ethenyl]tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis
JPS6388197A (ja) * 1986-09-30 1988-04-19 Tosoh Corp モノクロナル抗体の安定化方法
EP0410207B1 (de) * 1989-07-24 1997-01-22 Bayer Corporation Stabilisierung von hochgereinigten Proteinen

Also Published As

Publication number Publication date
ATE176868T1 (de) 1999-03-15
DE69228474T2 (de) 1999-06-24
JPH0525058A (ja) 1993-02-02
AU2330592A (en) 1993-02-23
AU662010B2 (en) 1995-08-17
WO1993001835A1 (en) 1993-02-04
EP0597101A4 (en) 1994-06-15
JP2966592B2 (ja) 1999-10-25
EP0597101B1 (de) 1999-02-24
EP0597101A1 (de) 1994-05-18

Similar Documents

Publication Publication Date Title
DE69228474D1 (de) STABILISIERTE AUFBEREITUNG MONOKLONALER MENSCHLICHER CLN-IgG ANTIKÖRPER
Finkelstein et al. Pathogenesis of experimental cholera: biologic activities of purified procholeragen A
Nutton From Galen to Alexander, aspects of medicine and medical practice in late antiquity
Heremans et al. Protective effect of anti‐interleukin (IL)‐6 antibody against endotoxin, associated with paradoxically increased IL‐6 levels
ATE205724T1 (de) Vakzine mit einem polysaccharide antigen- trägerprotein konjugat und freien trägerprotein
ATE122357T1 (de) Polypeptide mit hormonwachstumsbefreiender wirkung.
KR880000098A (ko) 콘드로이틴 설페이트 면역자극 조성물
ZA876807B (en) Monoclonal antibodies against human tumor necrosis factor(tnf),and use thereof
SE8204064L (sv) Vevnadslim samt sett for dess framstellning
RU92016463A (ru) Применение производных цистина для изготовления лекарственных препаратов с иммуномоделирующим действием, фармацевтические композиции на их основе
ES2102360T3 (es) Proteina de la superficie celular asociada a linfocitos.
OA08749A (fr) Vaccins dont l'épitope caractéristique est incorporé dans une protéine de picornavirus, notamment de poliovirus.
DE3685651D1 (de) Den antigenischen und immunogenischen determinanten von wichtigen neutralisierenden proteinen des rotavirus entsprechende peptide.
ATE174794T1 (de) Parenteral anzuwendende aminosäuren enthaltende zubereitungen zur bekämpfung von hypotension und verwandten pathologien
ATE174625T1 (de) Rekombinante hybride porinepitope
GEP20002257B (en) Method for Reducing Fibrin Accumulation Speed, Prophylactics of Thrombus Complications and Treatment of Blood Vessels Diseases, Medicinal Composition and Medicinal Species
FR2577048B1 (fr) Reactif pour le dosage par hemagglutination des anticorps contre les toxines bacteriennes, procede de preparation et son application
ATE63316T1 (de) Verwendung von n, n'-bis-l-aminosaeure-lcystinpeptiden in aminosaeure-praeparaten fuer orale und parenterale ernaehrung.
ES2060695T3 (es) Concentrados terapeuticos de igm.
MA21448A1 (fr) Procede de preparation de structures peptidiques et immunogenes les contenant destines au controle de la fertilite.
FI92716C (fi) Uudet monoklonaaliset vasta-aineet IFN-omegalle, niiden valmistusmenetelmät ja niiden käyttö IFN-omegan puhdistamiseen ja osoittamiseen
EP0213595A3 (de) Transferrine und ihre Verwendung
ATE175357T1 (de) Empfängnisverhütender impfstoff
RU95104722A (ru) Способ получения антител к коринебактериям дифтерии
Shin et al. Effect of Cycloheximide on the Specific Activity of Na+-K+-activated Adenosine Triphosphatase in Human Neonatal Erythrocytes

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee